These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 17510061)

  • 21. A concerted structural transition in the plasminogen activator inhibitor-1 mechanism of inhibition.
    Blouse GE; Perron MJ; Thompson JH; Day DE; Link CA; Shore JD
    Biochemistry; 2002 Oct; 41(40):11997-2009. PubMed ID: 12356300
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Crystal structure of human maspin, a serpin with antitumor properties: reactive center loop of maspin is exposed but constrained.
    Al-Ayyoubi M; Gettins PG; Volz K
    J Biol Chem; 2004 Dec; 279(53):55540-4. PubMed ID: 15501821
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Type-1 plasminogen-activator inhibitor -- conformational differences between latent, active, reactive-centre-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibility.
    Egelund R; Schousboe SL; Sottrup-Jensen L; Rodenburg KW; Andreasen PA
    Eur J Biochem; 1997 Sep; 248(3):775-85. PubMed ID: 9342229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.
    Rodenburg KW; Kjoller L; Petersen HH; Andreasen PA
    Biochem J; 1998 Jan; 329 ( Pt 1)(Pt 1):55-63. PubMed ID: 9405275
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The tumor suppressor maspin does not undergo the stressed to relaxed transition or inhibit trypsin-like serine proteases. Evidence that maspin is not a protease inhibitory serpin.
    Pemberton PA; Wong DT; Gibson HL; Kiefer MC; Fitzpatrick PA; Sager R; Barr PJ
    J Biol Chem; 1995 Jun; 270(26):15832-7. PubMed ID: 7797587
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulation of serpin reaction through stabilization of transient intermediate by ligands bound to alpha-helix F.
    Komissarov AA; Zhou A; Declerck PJ
    J Biol Chem; 2007 Sep; 282(36):26306-15. PubMed ID: 17613529
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop.
    Dekker RJ; Eichinger A; Stoop AA; Bode W; Pannekoek H; Horrevoets AJ
    J Mol Biol; 1999 Oct; 293(3):613-27. PubMed ID: 10543954
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proteinase specificity and functional diversity in point mutants of plasminogen activator inhibitor 1.
    Gils A; Declerck PJ
    J Biol Chem; 1997 May; 272(19):12662-6. PubMed ID: 9139722
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conformational changes of the reactive-centre loop and beta-strand 5A accompany temperature-dependent inhibitor-substrate transition of plasminogen-activator inhibitor 1.
    Kjøller L; Martensen PM; Sottrup-Jensen L; Justesen J; Rodenburg KW; Andreasen PA
    Eur J Biochem; 1996 Oct; 241(1):38-46. PubMed ID: 8898886
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Maspin regulates hypoxia-mediated stimulation of uPA/uPAR complex in invasive breast cancer cells.
    Amir S; Margaryan NV; Odero-Marah V; Khalkhali-Ellis Z; Hendrix MJ
    Cancer Biol Ther; 2005 Apr; 4(4):400-6. PubMed ID: 15846059
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interfering with the inhibitory mechanism of serpins: crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide.
    Xue Y; Björquist P; Inghardt T; Linschoten M; Musil D; Sjölin L; Deinum J
    Structure; 1998 May; 6(5):627-36. PubMed ID: 9634700
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunohistochemical detection of uPA, uPAR, PAI-1, and maspin in ameloblastic tumors.
    Kumamoto H; Ooya K
    J Oral Pathol Med; 2007 Sep; 36(8):488-94. PubMed ID: 17686008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of myxomaviral serpin reactive site loop sequences that regulate innate immune responses.
    Dai E; Viswanathan K; Sun YM; Li X; Liu LY; Togonu-Bickersteth B; Richardson J; Macaulay C; Nash P; Turner P; Nazarian SH; Moyer R; McFadden G; Lucas AR
    J Biol Chem; 2006 Mar; 281(12):8041-50. PubMed ID: 16407226
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride.
    Jankun J; Skrzypczak-Jankun E
    Cancer Biochem Biophys; 1999 Jul; 17(1-2):109-23. PubMed ID: 10738907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structural determinants in the stability of the serpin/proteinase complex.
    De Taeye B; Verbeke K; Compernolle G; Biesemans W; Gils A; Declerck PJ
    Biochem Biophys Res Commun; 2003 Aug; 307(3):529-34. PubMed ID: 12893254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tissue plasminogen activator binds to human vascular smooth muscle cells by a novel mechanism. Evidence for a reciprocal linkage between inhibition of catalytic activity and cellular binding.
    Werner F; Razzaq TM; Ellis V
    J Biol Chem; 1999 Jul; 274(31):21555-61. PubMed ID: 10419460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence for the regulation of urokinase and tissue type plasminogen activators by the serpin, protein C inhibitor, in semen and blood plasma.
    España F; Estellés A; Fernández PJ; Gilabert J; Sánchez-Cuenca J; Griffin JH
    Thromb Haemost; 1993 Dec; 70(6):989-94. PubMed ID: 8165623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A peptide mimicking the C-terminal part of the reactive center loop induces the transition to the latent form of plasminogen activator inhibitor type-1.
    D'Amico S; Martial JA; Struman I
    FEBS Lett; 2012 Mar; 586(6):686-92. PubMed ID: 22449964
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypoxia effects: implications for maspin regulation of the uPA/uPAR complex.
    Schaefer JS; Zhang M
    Cancer Biol Ther; 2005 Sep; 4(9):1033-5. PubMed ID: 16123583
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Crystal Structure of the Michaelis Complex between Tissue-type Plasminogen Activator and Plasminogen Activators Inhibitor-1.
    Gong L; Liu M; Zeng T; Shi X; Yuan C; Andreasen PA; Huang M
    J Biol Chem; 2015 Oct; 290(43):25795-804. PubMed ID: 26324706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.